Stress Disorders, Post-TraumaticQueST2023NCT05569915
Project QueST 2023: Queer Survivors of Trauma
A study testing Trauma Expressive Writing and Stigma Expressive Writing in people with Stress Disorders, Post-Traumatic and Drinking Heavy, run by Syracuse University at 1 site in United States.
Trial summary
This study aims to test the initial efficacy of tailored online writing interventions specifically designed for sexual minority women, transgender individuals, and/or nonbinary people to target the primary outcomes: posttraumatic stress disorder (PTSD) symptom severity and hazardous drinking. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Stress Disorders, Post-Traumatic, Drinking Heavy
- What is being tested?
- Trauma Expressive Writing and Stigma Expressive Writing
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 131 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jun 2023to 30 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- being at least 18 years of age
- reporting English fluency
- identifying as sexual minority women, inclusive of gender-diverse people
- living in the United States (US)
- reporting one or more Criterion A traumatic events
- having internet and email access
- not having received inpatient psychiatric support in the past six months
Who cannot join
- failing an inclusion criterion
Trial locations and contacts
1 site in 1 country.
About this study
This study aims to test the initial efficacy of tailored online writing interventions specifically designed for sexual minority women, transgender individuals, and/or nonbinary people to target the primary outcomes: posttraumatic stress disorder (PTSD) symptom severity and hazardous drinking.
Read the detailed description
This study aims to provide a novel method for adapting and testing evidence-based expressive writing (EW) treatments for trauma-exposed sexual minority women (SMW) and gender diverse individuals. The investigators will (1) describe the development and components of the proposed EW treatments, (2) discuss our plan for evaluating acceptability and feasibility of the proposed study, (3) identify steps for characterizing preliminary efficacy of EW treatments in reducing PTSD symptom severity and hazardous drinking levels compared to control, and (4) highlight our strategy for preliminarily evaluating mediators and moderators of treatment efficacy.
- Conditions
- Stress Disorders, Post-Traumatic, Drinking Heavy
- Being tested
- Trauma Expressive Writing, Stigma Expressive Writing, Control
- Keywords
- sexual trauma, PTSD symptoms, coping, LGBTQ, lesbian, bisexual, Sexual and Gender Minorities, Alcohol-Related Disorders
- Medical subject headings
- Stress Disorders, Post-Traumatic, Sexual Trauma, Homosexuality, Female, Bisexuality, Coitus, Alcohol-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Trauma Expressive WritingBehavioural
Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.
Stigma Expressive WritingBehavioural
Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.
ControlBehavioural
Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.
| Study group | Role | What they receive |
|---|---|---|
| Trauma Expressive Writing | Experimental | In the trauma condition, we ask participants to write about a traumatic experience, prompting them to write their very deepest thoughts and feelings about the most traumatic experience of their entire life or an extremely important stressful, upsetting, or emotional issue that has affected them. Receives: Behavioral: Trauma Expressive Writing |
| Stigma Expressive Writing | Experimental | In the stigma condition, we ask participants to write about an experience of stigma, prompting them to write about their very deepest thoughts and feelings about the most difficult or painful experience of stigma or bias (e.g., prejudice, bullying, rejection, discrimination) based on one or more of their identities (e.g., race/ethnicity, gender identity, sexual identity, religion) that they have faced. Receives: Behavioral: Stigma Expressive Writing |
| Control | Placebo comparator | In the control condition, we ask participants to write about their day, prompting them to write about what they did yesterday from the time they got up until the time they went to bed. Receives: Behavioral: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in PTSD symptom severity
Posttraumatic stress disorder (PTSD) symptoms will be measured with the Psychometric Properties of the Posttraumatic Diagnostic Scale for DSM-5 (PDS-5). The PDS-5 is a 24-item self-report measure designed to assess the severity of DSM-5 PTSD symptoms. The 24-item scale comprises a checklist of traumatic event types the individual has experienced, identification of the most distressing traumatic event, and an assessment of PTSD symptoms. The assessment of PTSD symptoms yields a total score and three subscales (re-experiencing, avoidance, and arousal), and a cutoff score of 28 or higher indicates a probable PTSD diagnosis. Items are scored 1 = once a week or less/a little to 4 = 6 or more times a week/severe. At baseline and 3-month follow-up assessments, participants will complete the PDS-5 in reference to the past month. At the one-week follow-up assessment, participants will complete the PDS-5 in reference to the past week.
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in hazardous drinking levels
The Alcohol Use Disorders Identification Test (AUDIT) will be used to measure hazardous drinking levels. The AUDIT is a 10-item screening measure of problematic alcohol use with individual items ranging from 0 to 4. Scores of 8 and higher are thought to reflect hazardous alcohol use. At baseline and 3-month follow-up assessments, participants will complete the AUDIT in reference to the past month.
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in drinking quantity
To assess drinking quantity in the past week, the investigators will ask participants one question that assesses retrospective estimates for number of drinks consumed on average (in a typical week). The investigators will assess change in the total number of drinks consumed on a typical week in the past month from baseline to total number of drinks consumed in the past week at one-week follow-up and from baseline to total number of drinks consumed in a typical week in the past month at 3-months follow-up assessment. At baseline and 3-month follow-up assessments, participants will complete the hazardous drinking quantity question in reference to a typical week during the past month. At the one-week follow-up assessment, participants will complete the hazardous drinking quantity question in reference to the past week.
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in heavy drinking frequency
The investigators will assess the number of heavy drinking days (days where participants assigned female or intersex at birth consume ≥4 standard drinks and participants assigned male at birth consume ≥5 standard drinks). Response options range from 0 = never to 4 = almost every day where higher scores represent greater heavy drinking frequency. The investigators will assess change in frequency of heavy drinking days in the past month from baseline to frequency of heavy drinking days in the past week at one-week follow-up and from baseline to frequency of heavy drinking days in the past month at 3-months follow-up. At baseline and 3-month follow-up assessments, participants will report frequency of heavy drinking days over the past month. At the one-week follow-up assessment, participants will report frequency of heavy drinking days over the past week.
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Secondary outcomes (19)
Change in trauma centrality.
Trauma centrality will be measured with the Centrality of Events Scale (CSE), which assesses to what degree an event is integrated into an individual's life story and identity. The 20-item questionnaire represents three factors of which the memory of the event has become an (a) reference point for everyday inferences, (b) a core part of personal identity, and (c) a turning point in the life story. Items are rated on a scale from 1 (totally disagree) to 5 (totally agree), and summed to yield a total score.
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in coping.
Coping will be measured using the Brief COPE, a 28-item measure that assesses coping strategies during stress. The Brief COPE consists of 14 subscales with two items per subscale. The investigators will use eight items across four subscales: self-distraction, denial, behavioral disengagement, and self-blame. Respondents rate items using a four-point Likert scale ranging from 1 ("I haven't been doing this at all") to 4 ("I've been doing this a lot"). Greater scores indicate greater use of self-distraction, denial, behavioral disengagement, and self-blame to cope with stress.
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in sexual minority identity-related experiences
Sexual minority identity-related experiences will be assessed with the Lesbian, Gay, Bisexual Identity Scale. This scale contains 27 items and assesses concealment, internalized stigma, and anticipated stigma, among other identity-related constructs. Responses range from 1 (Disagree strongly) to 6 (Agree strongly). Subscale scores are computed by reverse-scoring items as needed and averaging subscale item ratings. Subscale composition is as follows: Acceptance Concerns (5, 9, 16), Concealment Motivation (1, 4, 19), Identity Uncertainty (3, 8, 14, 22), Internalized Homonegativity (2, 20, 27), Difficult Process (12, 17, 23), Identity Superiority (7, 10, 18), Identity Affirmation (6, 13, 26), and Identity Centrality (11, 15, 21, 24, 25).
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in perceived stress.
Perceived stress will be measured with the Ten-Item Perceived Stress Scale (PSS-10), a 10-item self-reporting measure to assess the level of stress experienced by the respondents. Items are scored on a five-point Likert scale, from 0 (never) to 4 (very often). Greater scores indicate greater perceived stress. At baseline and 3-month follow-up assessments, participants will complete the PSS-10 in reference to the past month. At the one-week follow-up assessment, participants will complete the PSS-10 in reference to the past week.
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in depression and anxiety symptoms.
Depression and anxiety symptoms will be assessed using the Brief Symptom Inventory (BSI). The BSI uses 18 items across 2 subscales to capture the extent to which an individual has been distressed by various symptoms of depression and anxiety over the past week (e.g., "Nervousness or shakiness inside" for the anxiety subscale and "Feeling hopeless about the future" for the depression subscale). Possible response options range from 0 (Not at all) to 4 (Extremely). Greater scores indicate greater depression and anxiety symptom severity. At baseline, 1-week, and 3-month follow-up assessments, participants will complete the depression and anxiety subscales in reference to the past week.
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in emotion regulation.
Emotion regulation will be assessed with the Difficulties in Emotion Regulation Scale (DERS). The Difficulties in Emotion Regulation Scale contains 36 items that capture the extent to which an individual generally has trouble regulating their emotions. The investigators will use the distress tolerance and ability to tolerate negative emotions subscales. Possible responses range from 1 (Almost never; 0-10% of the time) to 5 (Almost always; 91-100% of the time). Greater total scores indicate greater difficulties with emotion regulation (i.e., emotion dysregulation).
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in impulsivity.
Impulsivity will be measured with the Short UPPS-P, a 20-item, self-report questionnaire that measures five dimensions of impulsive behavior (negative urgency, lack of premeditation, lack of perseveration, sensation seeking, and positive urgency). Each item is rated on a 4-point scale, from Agree strongly (1) to Disagree strongly (4). The investigators will use the negative urgency subscale from the UPPS-P. Items are reverse scored such that higher scores indicate greater negative urgency (i.e., impulsivity).
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in self-efficacy.
Self-efficacy will be measured by the Generalized Self-Efficacy Scale (GSES). The GSES is a measure of general self-efficacy. It consists of 10 items. Respondents rate each item on a 1 (not true at all) to 4 (exactly true) scale. Higher scores represent greater self-efficacy.
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in attachment style.
Attachment style will be measured using the Experiences in Close Relationships - Short form (ECR- SF). The investigators will use the 6-item anxiety subscale and 6-item avoidance subscale. The ECR uses a 6-point scale to assess both anxious attachment and avoidant attachment. Response options range from 1 = strongly disagree to 6 = strongly agree where higher scores represent greater anxiety and avoidant attachment styles.
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in self-compassion.
Self-compassion will be measured with the Self-Compassion Scale (SCS), a 26-item self-report measure of the degree to which individuals exhibit a kind and accepting attitude toward themselves. The investigators will use the following subscales of the SCS: self-kindness, common humanity, and mindfulness. Responses are on a Likert-type scale from 1 = almost never to 5 = almost always, with higher scores indicating greater self-compassion.
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in suicidality.
Suicidality will be measured with the SBQ-R. Suicide ideation/behavior will be assessed using Item 1 of the SBQ-R. The original SBQ-R consists of four items but only the aforementioned item was used in the current study due to space constraints. However, Item 1 of the SBQ-R has been recommended for screening purposes and has repeatedly been used in clinical and non-clinical samples. Response options range from 0 = Never to 5 = I have attempted to kill myself, and really hoped to die. At baseline and 3-month follow-up assessments, participants will complete the SBQ-R in reference to the past 3 months.
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in hope.
Hope was measured with a hope scale - a single question. Participants will rate their answers on a visual analog scale from 1 ("not at all hopeful") to 10 ("very hopeful"). Higher scores represent greater hope.
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in substance use.
Substance use will be assessed using the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST), a screening measure of severity of involvement using alcohol, cannabis, cocaine, prescription stimulants, amphetamine-type stimulants, sedatives and sleeping pills, hallucinogens, inhalants, street opioids, prescription opioids, and other miscellaneous drugs. Response options include 0 = no, 1 = yes, but not in the past 3 months, and 2 = yes, in the past 3 months. At baseline and 3-month follow-up assessments, participants will complete the ASSIST in reference to past 3 months use.
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in problematic drug use.
Problematic drug use will be measured with the Drug Use Disorders Identification Test (DUDIT). The DUDIT is a self-report instrument composed of 11 items identifying problems related to substance use. Scoring of the DUDIT is two-fold: items 1 to 9 are scored on a five-point Likert scale, while items 10 and 11 are scored on a three-point scale. The overall score is calculated by summing the scores on all items. Higher scores represent greater problematic drug use. At baseline and 3-month follow-up assessments, participants will complete the DUDIT in reference to past 3 months use.
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in heavy drinking presence
Heavy drinking presence will be measured by asking if participants had 4 of more drinks if assigned female at birth or intersex OR 5 or more drinks if assigned male at birth in the past 3 months. At baseline and 3-month follow-up assessments, participants will answer the question about heavy drinking presence in reference to past 3 months.
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in alexithymia
Alexithymia will be measured with the Perth Alexithymia Questionnaire (4-item negative-difficulty identifying feelings subscale and 4-item negative-difficulty describing feelings subscale). The Perth Alexithymia Questionnaire (PAQ) is a 24-item self-report measure of alexithymia answered on a 7-point Likert scale (1 = strongly disagree, 7 = strongly agree). Subscales can be summed to derive an overall alexithymia total score, with higher scores indicative of higher levels of alexithymia.
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in dissociation
Dissociation will be measured with the Brief Dissociative Experiences Scale (DES-B) - Modified, which was recently Modified for DSM-5. The DES-B is an eight items scale that measures the phenomena of dissociative experience over the past week, not necessarily pathological dissociation. Response options range from 0 to 4, with 0 indicating not at all, and 4 more than once a day. At baseline, 1-week, and 3-month follow-up assessments, participants will complete the DES-B in reference to the past week.
Measured: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in general health perceptions
Physical health symptoms will be assessed using the first item of the Short-Form Health Survey (SF-12). Response options are on a 5-point Likert-scale with higher scores indicating worse general health perceptions. Scores range from Excellent (0) to Poor (4).
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in physical health symptoms
The investigators will also assess physical health symptoms using the Patient Health Questionnaire - 15 (PHQ-15), a self-administered somatic symptoms subscale derived from the full PHQ. Participants are asked to rate the severity of their symptoms during the previous 4 weeks on a 3-point scale as either 0 ("not bothered at all"), 1 ("bothered a little") or 2 ("bothered a lot"). Total symptom severity score ranged from 0 to 30. At baseline and 3-month follow-up assessments, participants will answer the questions about physical health symptoms in reference to the past month.
Measured: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2022
- Study start1 Jun 2023
- Primary completion30 Nov 2024
- Study completion30 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (23)Papers the sponsor has linked to this study.
- Other trials for Stress Disorders, Post-TraumaticStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 131 participants (actual)
Sponsor and investigators
- Lead sponsor
- Syracuse University
- Sponsor type
- University, hospital or other
- Collaborators
- Yale University, Massachusetts General Hospital
- Responsible party
- Principal investigator, Jillian Scheer, Syracuse University
- Investigators
- Jillian R Scheer, PhD, Principal investigator, Syracuse University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05569915
- Sponsor's protocol ID
- 20-306
- Acronym
- QueST2023
- Status last verified
- Mar 2026
- First submitted
- 3 Oct 2022
- Last updated
- 20 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data for all primary and secondary outcome measures will be made available.
Publications
World Health Organization, Babor, Thomas F., Higgins-Biddle, John C., Saunders, John B. Monteiro, Maristela G. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for use in primary health care, 2nd ed. World Health Organization. 2001. https://apps.who.int/iris/handle/10665/67205
Dalenberg C, Carlson E. New versions of the Dissociative Experiences Scale: The DES-R (revised) and the DES-B (brief). Paper presented at the International Society for Traumatic Stress Studies Annual Meeting. 2010;26:203. https://istss.org/meetings-events/meeting-archives/2010-annual-meeting-archives.aspx
Preece D, Becerra R, Robinson K, Dandy J, Allan A. The psychometric assessment of alexithymia: Development and validation of the Perth Alexithymia Questionnaire. Pers Individ Dif. 2018;132:32-44. doi: 10.1016/j.paid.2018.05.011
Salomon K, Bosson JK, El-Hout M, Kiebel E, Kuchynka SL, Shepard SL. The Experiences with Ambivalent Sexism Inventory (EASI). Basic Appl Soc Psychol. 2020;42(4):235-253. doi: 10.1080/01973533.2020.1747467
Tebbe EA, Moradi B, Wilson E, Bell HL, Connelly K, Lenzen A. Development and psychometric evaluation of the Sexual Minority Women's Sexual Objectification Experiences Scale. J Couns Psychol. 2021 Oct;68(5):501-514. doi: 10.1037/cou0000547. Epub 2021 Mar 25.
PubMed 33764114Gomez JM. What's the harm? Internalized prejudice and cultural betrayal trauma in ethnic minorities. Am J Orthopsychiatry. 2019;89(2):237-247. doi: 10.1037/ort0000367. Epub 2018 Nov 8.
PubMed 30407029Hildebrand M. The Psychometric Properties of the Drug Use Disorders Identification Test (DUDIT): A Review of Recent Research. J Subst Abuse Treat. 2015 Jun;53:52-9. doi: 10.1016/j.jsat.2015.01.008. Epub 2015 Jan 31.
PubMed 25682718Carter G, Yu Z, Aryana Bryan M, Brown JL, Winhusen T, Cochran G. Validation of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool with the WHO alcohol, smoking, and substance Involvement screening test (ASSIST). Addict Behav. 2022 Mar;126:107178. doi: 10.1016/j.addbeh.2021.107178. Epub 2021 Nov 10.
PubMed 34802777Berntsen D, Rubin DC. The centrality of event scale: a measure of integrating a trauma into one's identity and its relation to post-traumatic stress disorder symptoms. Behav Res Ther. 2006 Feb;44(2):219-31. doi: 10.1016/j.brat.2005.01.009.
PubMed 16389062Carver CS. You want to measure coping but your protocol's too long: consider the brief COPE. Int J Behav Med. 1997;4(1):92-100. doi: 10.1207/s15327558ijbm0401_6.
PubMed 16250744Neff, K. D. (2003). Development and validation of a scale to measure self-compassion. Self and Identity, 2, 223-250.
Osman A, Bagge CL, Gutierrez PM, Konick LC, Kopper BA, Barrios FX. The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples. Assessment. 2001 Dec;8(4):443-54. doi: 10.1177/107319110100800409.
PubMed 11785588Gandhi SK, Salmon JW, Zhao SZ, Lambert BL, Gore PR, Conrad K. Psychometric evaluation of the 12-item short-form health survey (SF-12) in osteoarthritis and rheumatoid arthritis clinical trials. Clin Ther. 2001 Jul;23(7):1080-98. doi: 10.1016/s0149-2918(01)80093-x.
PubMed 11519772Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002 Mar-Apr;64(2):258-66. doi: 10.1097/00006842-200203000-00008.
PubMed 11914441Mohr JJ, Kendra MS. Revision and extension of a multidimensional measure of sexual minority identity: the Lesbian, Gay, and Bisexual Identity Scale. J Couns Psychol. 2011 Apr;58(2):234-245. doi: 10.1037/a0022858.
PubMed 21319899
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Project QueST 2023: Queer Survivors of Trauma
- ClinicalTrials.gov ID
- NCT05569915
- Acronym / sponsor ID
- QueST2023 / 20-306
- Conditions
- Stress Disorders, Post-Traumatic, Drinking Heavy
- Keywords
- sexual trauma, PTSD symptoms, coping, LGBTQ, lesbian, bisexual, Sexual and Gender Minorities, Alcohol-Related Disorders
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 131 participants (actual)
- Lead sponsor
- Syracuse UniversityUniversity, hospital or other
- Collaborators
- Yale University, Massachusetts General Hospital
- Study start
- 1 Jun 2023 (actual)
- Primary completion
- 30 Nov 2024 (actual)
- Study completion
- 30 Nov 2024 (actual)
- First posted
- 6 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to test the initial efficacy of tailored online writing interventions specifically designed for sexual minority women, transgender individuals, and/or nonbinary people to target the primary outcomes: posttraumatic stress disorder (PTSD) symptom severity and hazardous drinking.
Detailed description
This study aims to provide a novel method for adapting and testing evidence-based expressive writing (EW) treatments for trauma-exposed sexual minority women (SMW) and gender diverse individuals. The investigators will (1) describe the development and components of the proposed EW treatments, (2) discuss our plan for evaluating acceptability and feasibility of the proposed study, (3) identify steps for characterizing preliminary efficacy of EW treatments in reducing PTSD symptom severity and hazardous drinking levels compared to control, and (4) highlight our strategy for preliminarily evaluating mediators and moderators of treatment efficacy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Trauma Expressive Writing | Experimental | Behavioral: Trauma Expressive WritingIn the trauma condition, we ask participants to write about a traumatic experience, prompting them to write their very deepest thoughts and feelings about the most traumatic experience of their entire life or an extremely important stressful, upsetting, or emotional issue that has affected them. |
| Stigma Expressive Writing | Experimental | Behavioral: Stigma Expressive WritingIn the stigma condition, we ask participants to write about an experience of stigma, prompting them to write about their very deepest thoughts and feelings about the most difficult or painful experience of stigma or bias (e.g., prejudice, bullying, rejection, discrimination) based on one or more of their identities (e.g., race/ethnicity, gender identity, sexual identity, religion) that they have faced. |
| Control | Placebo comparator | Behavioral: ControlIn the control condition, we ask participants to write about their day, prompting them to write about what they did yesterday from the time they got up until the time they went to bed. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- being at least 18 years of age
- reporting English fluency
- identifying as sexual minority women, inclusive of gender-diverse people
- living in the United States (US)
- reporting one or more Criterion A traumatic events
Key exclusion criteria (1 listed)
- failing an inclusion criterion
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Trauma Expressive WritingParticipants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days. | Behavioural | Trauma Expressive Writing |
| Stigma Expressive WritingParticipants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days. | Behavioural | Stigma Expressive Writing |
| ControlParticipants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies. | Behavioural | Control |
Primary outcome
Change in PTSD symptom severity
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Posttraumatic stress disorder (PTSD) symptoms will be measured with the Psychometric Properties of the Posttraumatic Diagnostic Scale for DSM-5 (PDS-5). The PDS-5 is a 24-item self-report measure designed to assess the severity of DSM-5 PTSD symptoms. The 24-item scale comprises a checklist of traumatic event types the individual has experienced, identification of the most distressing traumatic event, and an assessment of PTSD symptoms. The assessment of PTSD symptoms yields a total score and three subscales (re-experiencing, avoidance, and arousal), and a cutoff score of 28 or higher indicates a probable PTSD diagnosis. Items are scored 1 = once a week or less/a little to 4 = 6 or more times a week/severe. At baseline and 3-month follow-up assessments, participants will complete the PDS-5 in reference to the past month. At the one-week follow-up assessment, participants will complete the PDS-5 in reference to the past week.
Change in hazardous drinking levels
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
The Alcohol Use Disorders Identification Test (AUDIT) will be used to measure hazardous drinking levels. The AUDIT is a 10-item screening measure of problematic alcohol use with individual items ranging from 0 to 4. Scores of 8 and higher are thought to reflect hazardous alcohol use. At baseline and 3-month follow-up assessments, participants will complete the AUDIT in reference to the past month.
Change in drinking quantity
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
To assess drinking quantity in the past week, the investigators will ask participants one question that assesses retrospective estimates for number of drinks consumed on average (in a typical week). The investigators will assess change in the total number of drinks consumed on a typical week in the past month from baseline to total number of drinks consumed in the past week at one-week follow-up and from baseline to total number of drinks consumed in a typical week in the past month at 3-months follow-up assessment. At baseline and 3-month follow-up assessments, participants will complete the hazardous drinking quantity question in reference to a typical week during the past month. At the one-week follow-up assessment, participants will complete the hazardous drinking quantity question in reference to the past week.
Change in heavy drinking frequency
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
The investigators will assess the number of heavy drinking days (days where participants assigned female or intersex at birth consume ≥4 standard drinks and participants assigned male at birth consume ≥5 standard drinks). Response options range from 0 = never to 4 = almost every day where higher scores represent greater heavy drinking frequency. The investigators will assess change in frequency of heavy drinking days in the past month from baseline to frequency of heavy drinking days in the past week at one-week follow-up and from baseline to frequency of heavy drinking days in the past month at 3-months follow-up. At baseline and 3-month follow-up assessments, participants will report frequency of heavy drinking days over the past month. At the one-week follow-up assessment, participants will report frequency of heavy drinking days over the past week.
19 secondary outcomes
Change in trauma centrality.
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in coping.
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in sexual minority identity-related experiences
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in perceived stress.
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in depression and anxiety symptoms.
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in emotion regulation.
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in impulsivity.
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in self-efficacy.
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in attachment style.
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in self-compassion.
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in suicidality.
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in hope.
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in substance use.
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in problematic drug use.
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in heavy drinking presence
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in alexithymia
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in dissociation
Time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)
Change in general health perceptions
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Change in physical health symptoms
Time frame: Baseline (Pre-intervention) and Three-month Follow-up (3 months post first treatment session)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2026.
- BackgroundWorld Health Organization, Babor, Thomas F., Higgins-Biddle, John C., Saunders, John B. Monteiro, Maristela G. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for use in primary health care, 2nd ed. World Health Organization. 2001. https://apps.who.int/iris/handle/10665/67205
- BackgroundDalenberg C, Carlson E. New versions of the Dissociative Experiences Scale: The DES-R (revised) and the DES-B (brief). Paper presented at the International Society for Traumatic Stress Studies Annual Meeting. 2010;26:203. https://istss.org/meetings-events/meeting-archives/2010-annual-meeting-archives.aspx
- BackgroundPreece D, Becerra R, Robinson K, Dandy J, Allan A. The psychometric assessment of alexithymia: Development and validation of the Perth Alexithymia Questionnaire. Pers Individ Dif. 2018;132:32-44. doi: 10.1016/j.paid.2018.05.011
- BackgroundSalomon K, Bosson JK, El-Hout M, Kiebel E, Kuchynka SL, Shepard SL. The Experiences with Ambivalent Sexism Inventory (EASI). Basic Appl Soc Psychol. 2020;42(4):235-253. doi: 10.1080/01973533.2020.1747467
- Background: PubMed 33764114Tebbe EA, Moradi B, Wilson E, Bell HL, Connelly K, Lenzen A. Development and psychometric evaluation of the Sexual Minority Women's Sexual Objectification Experiences Scale. J Couns Psychol. 2021 Oct;68(5):501-514. doi: 10.1037/cou0000547. Epub 2021 Mar 25.
- Background: PubMed 30407029Gomez JM. What's the harm? Internalized prejudice and cultural betrayal trauma in ethnic minorities. Am J Orthopsychiatry. 2019;89(2):237-247. doi: 10.1037/ort0000367. Epub 2018 Nov 8.
- Background: PubMed 25682718Hildebrand M. The Psychometric Properties of the Drug Use Disorders Identification Test (DUDIT): A Review of Recent Research. J Subst Abuse Treat. 2015 Jun;53:52-9. doi: 10.1016/j.jsat.2015.01.008. Epub 2015 Jan 31.
- Background: PubMed 34802777Carter G, Yu Z, Aryana Bryan M, Brown JL, Winhusen T, Cochran G. Validation of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool with the WHO alcohol, smoking, and substance Involvement screening test (ASSIST). Addict Behav. 2022 Mar;126:107178. doi: 10.1016/j.addbeh.2021.107178. Epub 2021 Nov 10.
- Background: PubMed 16389062Berntsen D, Rubin DC. The centrality of event scale: a measure of integrating a trauma into one's identity and its relation to post-traumatic stress disorder symptoms. Behav Res Ther. 2006 Feb;44(2):219-31. doi: 10.1016/j.brat.2005.01.009.
- Background: PubMed 16250744Carver CS. You want to measure coping but your protocol's too long: consider the brief COPE. Int J Behav Med. 1997;4(1):92-100. doi: 10.1207/s15327558ijbm0401_6.
- BackgroundNeff, K. D. (2003). Development and validation of a scale to measure self-compassion. Self and Identity, 2, 223-250.
- Background: PubMed 11785588Osman A, Bagge CL, Gutierrez PM, Konick LC, Kopper BA, Barrios FX. The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples. Assessment. 2001 Dec;8(4):443-54. doi: 10.1177/107319110100800409.
- Individual participant dataSharing planned: Yes. De-identified individual participant data for all primary and secondary outcome measures will be made available.
Related trials for Stress Disorders, Post-Traumatic
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Not yet recruitingPhase 3
Women Who Are Victims of Violence: Treatment of PTSD Through Reactivation of Traumatic Memories Using Propranolol
Post-Traumatic Stress Disorder, PTSD
RecruitingPhase 4
The Effects of Orexin Antagonism on Fear Extinction in PTSD
Insomnia, PTSD
Recruiting
Advancing Skills Through Consultation, Education, and Novel Technologies
PTSD - Post Traumatic Stress Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jillian R Scheer, PhD principal investigator
Syracuse University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Trauma Expressive Writing and Stigma Expressive Writing in people with Stress Disorders, Post-Traumatic and Drinking Heavy, run by Syracuse University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in PTSD symptom severity (time frame: Baseline (Pre-intervention), Immediate Post-intervention (1 week post first treatment session), and Three-month Follow-up (3 months post first treatment session)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05569915, which also lists 23 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.